What is the appropriate treatment for X-linked agammaglobulinemia?

• A. Bone marrow transplant
• B. Intravenous immunoglobulin (IV IG)
• C. Antibiotic prophylaxis
• D. Monoclonal antibody therapy

Answer: (B)

X-linked agammaglobulinemia is a primary immunodeficiency characterized by a markedly reduced level of immunoglobulins (antibodies) due to a defect in B-cell development resulting from a mutation in the BTK gene. Individuals with this condition lack functional B cells and, consequently, the ability to produce adequate antibodies, leading to increased susceptibility to recurrent bacterial infections.

The most appropriate treatment for patients with X-linked agammaglobulinemia is intravenous immunoglobulin (IV IG). This therapy provides the patient with the necessary antibodies they are unable to produce on their own. By administering IV IG, healthcare providers are able to help patients maintain adequate antibody levels, thus reducing the risk of infections and improving overall health.

While bone marrow transplant can provide a potential cure, it carries significant risks and is generally reserved for more severe cases or when other treatments fail. Antibiotic prophylaxis is an essential part of managing infections but does not address the underlying deficiency in antibody production. Monoclonal antibody therapy is also not the primary treatment for this condition; instead, it may be used to target specific diseases or infections but does not replace the need for overall antibody replacement that IV IG provides.

Consequently, the administration of intravenous